# Confirm ultra-low-dose immunotherapy so it can be afforded where most patients live

Source: https://onco.cc/ideas/idea-tr1-low-dose-immunotherapy-for-lmic/  
OnCo record `idea-tr1-low-dose-immunotherapy-for-lmic` (Idea). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A single-centre trial at Tata Memorial found that adding nivolumab at about a twentieth of the usual dose to chemotherapy improved outcomes in head and neck cancer. Confirmatory trials against standard-dose immunotherapy are needed before low-dose labels could make immunotherapy affordable for millions.

## Summary

Randomised confirmatory trials of low-dose PD-1 blockade (e.g., nivolumab 20 mg every three weeks, as tested at Tata Memorial in head and neck cancer with an OS benefit versus chemotherapy alone) in additional indications and against standard-dose immunotherapy, with PK and receptor-occupancy sub-studies, and a regulatory pathway for low-dose labels or guideline recommendations in resource-limited settings. Uncertainty is substantial: the evidence base is a single-centre trial and non-inferiority to full dose has not been shown.

## Fields

- Kind: Idea
- Last checked: 2026-09-08
- Hypothesis: Ultra-low-dose PD-1 blockade will show a survival benefit over chemotherapy alone in at least one further indication and will be within a pre-specified non-inferiority margin of standard dose in a direct comparison, at under 10 percent of the drug cost.
- Rationale: Receptor occupancy and early PK studies suggest saturation at doses well below label; the Tata trial provides randomised clinical evidence, and the access gap is the largest single inequity in modern oncology.
- Proposed test: A multicentre randomised trial in India and one African network comparing low-dose nivolumab plus chemotherapy with chemotherapy alone in NSCLC or cervical cancer, plus a non-inferiority arm against standard dose where affordable.
- Maturity: early-clinical
- Actor: research

## Sources

- Bottleneck evidence (Wrong doses): FDA Oncology Center of Excellence, Project Optimus: https://www.fda.gov/about-fda/oncology-center-excellence/project-optimus

## Connected records

- cancers: [Cervical cancer](https://onco.cc/cancers/cervical/), [Head and neck squamous cell carcinoma](https://onco.cc/cancers/head-and-neck/), [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- technologies: [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/)
- targets: [PD-1](https://onco.cc/targets/pd1/)
- drugs: [Nivolumab](https://onco.cc/drugs/nivolumab/)
- institutions: [Tata Memorial Centre](https://onco.cc/institutions/tata-memorial/)
- trials: [CheckMate 227](https://onco.cc/trials/checkmate-227/), [HARMONi-3](https://onco.cc/trials/harmoni-3/), [KEYNOTE-024 & KEYNOTE-189](https://onco.cc/trials/keynote-024-189/), [KEYNOTE-042](https://onco.cc/trials/keynote-042/), [KEYNOTE-A18 / ENGOT-cx11 / GOG-3047](https://onco.cc/trials/keynote-a18/)
- people: [Kumar Prabhash](https://onco.cc/people/prabhash-kumar/), [Vijay Patil](https://onco.cc/people/patil-vijay/)
- bottlenecks: [Most of the world has almost no cancer care](https://onco.cc/bottlenecks/b-global-access/), [Prices and value](https://onco.cc/bottlenecks/b-drug-pricing/), [Wrong doses](https://onco.cc/bottlenecks/b-dose-optimisation/)
- key papers: [CheckMate 017: nivolumab beats docetaxel in squamous lung cancer after chemotherapy](https://onco.cc/key-papers/paper-checkmate-017-nejm-2015/)
- roadmaps: [Global access and affordability roadmap: essential medicines and generics → biosimilars and frugal trials → reliance, pooling and homegrown innovation](https://onco.cc/roadmaps/global-access-roadmap/)

---
JSON: https://onco.cc/api/v1/entities/idea-tr1-low-dose-immunotherapy-for-lmic.json